JNJ vs PSTV

Johnson & Johnson (JNJ) remains a fundamentally strong, diversified healthcare conglomerate with an impressive market capitalization. While possessing robust financials, wide economic moats, and consistent performance, its sheer size ($579.46B) fundamentally misaligns with the criteria for 10x growth within a 3-5 year timeframe. A 10x return would necessitate a market cap exceeding $5.7 trillion, ...

Plus Therapeutics (PSTV) retains its high-risk, high-reward profile, but its immediate financial health has significantly improved since the last analysis. The company's cash position increased to over $16 million in 2025, moving stockholders' equity from negative to positive $3.9 million, substantially extending its cash runway. This addresses the primary financial risk previously identified. Fur...